View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 21, 2021updated 11 Jul 2022 2:14pm

More Covid-19 clinical trials seen in 2020 compared to 2021

This year has seen a 37.7% decrease in the number of Covid-19 clinical trials compared to last year, down from 3,483 to 2,170.

By GlobalData Healthcare

As new strains of Covid-19, such as Delta and now Omicron, continue to raise the number of cases around the world, sponsors are continuing clinical trials to find a therapeutic or vaccine. GlobalData’s Pharma Intelligence Centre has compiled data on these trials, showing a decrease in the number of Covid-19 trials from 2020 to 2021.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Last year, there were 3,483 Covid-19 clinical trials, while this year to date, there have been 2,170. This represents a 37.7% decrease between years. When looking at status, the biggest difference can be seen in suspended/terminated/withdrawn (S/T/W) trials. The difference between S/T/W trials in 2020 and 2021 was 75.9%. Last year also had more ongoing and completed trials while this year has had more planned trials, as seen in Figure 1.

Many factors could be contributing to these trends. One of the main reasons for the difference in completed trials is due to there having been more time from 2020 to the present to complete a trial compared to 2021. Other possible reasons include companies trying to be the frontrunners to receive approval. After the approvals of the three main Covid-19 vaccines in the US (those from Pfizer, Moderna and Janssen), sponsors continued testing for different age groups this year. For example, Pfizer received US Food and Drug Administration (FDA) expanded emergency use authorisation for children aged 5-11 years on 23 August this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena